Skip to content
Comparison

Tesamorelin vs MK-677 (Ibutamoren)

Tesamorelin and MK-677 (Ibutamoren) are commonly compared for visceral-fat targeted injectable therapy versus oral GH secretagogue. Tesamorelin is usually favored for indication-backed visceral adiposity evidence, while MK-677 (Ibutamoren) is often preferred for oral convenience and GH/IGF-1 support. This head-to-head analysis focuses on mechanism, trial outcomes, dosing context, evidence quality, regulatory status, and practical decision points for safer YMYL decision-making.

4.3(112 ratings)

Quick Answer

For visceral-fat targeted injectable therapy versus oral GH secretagogue, the better choice depends on your primary endpoint. Tesamorelin is stronger when the priority is clinician-guided visceral-fat endpoints. MK-677 (Ibutamoren) is stronger when the priority is oral convenience-first GH support. Use evidence grade, dose intensity, access constraints, and tolerability profile to match therapy to the patient profile rather than choosing by hype alone.

Head-to-Head Comparison

CriteriaTesamorelinMK-677 (Ibutamoren)
Primary mechanismFDA-approved GHRH analog for HIV lipodystrophyOral ghrelin-receptor agonist GH secretagogue
Strongest clinical signalStrong visceral-fat reduction in indicated populationsRaises GH/IGF-1 with oral convenience
Typical dosing context2 mg daily in approved protocol10-25 mg once daily
AdministrationSubcutaneous injectionOral daily
Evidence quality gradeStrong in HIV-lipodystrophy; moderate extrapolation outside indicationModerate human data in aging/body composition contexts
Regulatory statusFDA-approved for HIV-associated lipodystrophyInvestigational, not FDA-approved
Side-effect burdenMonitor glucose tolerance and IGF-1 trendsAppetite, edema, and insulin-resistance concerns
Cost/access contextHigh branded and clinic costOften lower cost than injectable GH pathways
Best candidate profileVisceral-adiposity endpoints with clinical supervisionUsers valuing oral administration over injections
Main limitationExpensive and indication-specific evidence concentrationMetabolic side effects may limit long-term use
Best use case in this comparisonclinician-guided visceral-fat endpointsoral convenience-first GH support

When to Choose Each

Choose Tesamorelin

Best for clinician-guided visceral-fat endpoints.

Choose MK-677 (Ibutamoren)

Best for oral convenience-first GH support.

Verdict

If the main goal is clinician-guided visceral-fat endpoints, Tesamorelin is usually the better first-line choice. If the main goal is oral convenience-first GH support, MK-677 (Ibutamoren) is typically the better fit. Reassess outcomes at 8-16 weeks with objective metrics, then adjust only when response, safety, or adherence data justify it. In high-risk populations, physician-guided personalization matters more than any generic ranking.

References

  1. Effects of tesamorelin on body composition and visceral fat in HIV-infected patients with abdominal fat accumulation (2010) — PubMed
  2. Tesamorelin reduces liver fat in HIV-associated NAFLD: a randomized, placebo-controlled trial (2016) — PubMed
  3. Tesamorelin effects on cognition in HIV-infected adults: the CLEAR study (2017) — PubMed
  4. Efficacy and safety of tesamorelin in treating HIV-associated lipodystrophy: a meta-analysis (2019) — PubMed

Compare Telehealth Providers

Find the right provider for your peptide therapy needs

Hims & Hers

Most Popular
4.3

Starting at $199/mo

Hims & Hers is a leading telehealth platform offering physician-supervised GLP-1 weight loss programs including compounded semaglutide and tirzepatide. Board-certified providers, async or video consults, and medication shipped to your door.

✓Large, established platform with strong physician network
✓Compounded semaglutide available where branded shortages exist
✓Easy async consult — no video call required
✗Does not offer a wide range of peptides beyond GLP-1s
✗Pricing is on the higher end for GLP-1 programs

Henry Meds

Most Peptides
4.2

Starting at $249/mo

Henry Meds is a telehealth provider specializing in hormone optimization and peptide therapy. Beyond GLP-1 weight loss, Henry Meds offers testosterone replacement therapy, growth hormone peptides, and other advanced hormonal protocols managed by licensed physicians.

✓Broadest peptide therapy menu of any major telehealth provider
✓Growth hormone peptides (sermorelin, ipamorelin, CJC-1295) available
✓Repair peptides including BPC-157 and TB-500
✗Higher starting price due to comprehensive programs
✗More complex onboarding including lab work requirements

Ro Body

Best Value
4.1

Starting at $149/mo

Ro Body is a telehealth weight management program powered by GLP-1 medications. Ro connects patients with licensed providers who prescribe compounded semaglutide or branded GLP-1 therapies depending on eligibility, paired with behavioral coaching.

✓Competitive pricing starting at $149/mo
✓Dedicated health coach included in program
✓Strong clinical protocols with lab-work integration
✗Narrower peptide offering — GLP-1s only
✗Video consult required for initial visit

Calibrate

4.0

Starting at $199/mo

Calibrate is a metabolic health company offering a one-year GLP-1 program built around four pillars: food, sleep, exercise, and emotional health. Calibrate works with insurance to cover medication costs and provides extensive behavioral coaching alongside prescriptions.

✓Insurance navigation support for medication coverage
✓Evidence-based one-year program with structured milestones
✓Four-pillar lifestyle coaching (food, sleep, exercise, emotional health)
✗Annual program commitment required
✗Primarily focused on GLP-1s — no broader peptide therapy

Found

3.9

Starting at $129/mo

Found is a weight management telehealth platform that combines GLP-1 medications with behavioral coaching and a supportive community. Found emphasizes a whole-person approach, pairing pharmacological treatment with lifestyle intervention for sustainable results.

✓One of the more affordable monthly program fees
✓Strong community and peer support features
✓Certified health coaches with regular check-ins
✗Medication billed separately from program fee — total cost can be higher
✗Limited peptide variety beyond standard GLP-1s

Sponsored · We may earn a commission. Learn more · Updated February 2026

Frequently Asked Questions

Which has stronger evidence for visceral-fat targeted injectable therapy versus oral GH secretagogue — Tesamorelin or MK-677 (Ibutamoren)?
Tesamorelin is graded as strong in hiv-lipodystrophy; moderate extrapolation outside indication evidence in this context, while MK-677 (Ibutamoren) is graded as moderate human data in aging/body composition contexts. In practice, strength depends on whether you prioritize clinician-guided visceral-fat endpoints or oral convenience-first GH support. Favor the option with endpoint data closest to your primary goal, and avoid extrapolating beyond studied populations.
Can Tesamorelin and MK-677 (Ibutamoren) be combined or sequenced?
Sometimes, but only with clinician oversight. A common framework is to start with one agent, track objective response for 8-16 weeks, then switch or sequence if outcomes plateau or tolerability is poor. Combination protocols may increase both cost and adverse-effect complexity, so they should be justified by clear endpoint-based rationale.
What should be monitored before and during treatment?
Baseline assessment should include diagnosis confirmation, comorbidity risk, and contraindications. During therapy, monitor target outcomes (symptoms, body composition, labs), adverse effects, and adherence burden. For endocrine/metabolic strategies, periodic glucose, lipids, organ function, and indication-specific labs help keep risk proportional to expected benefit.

Explore next